| P50 | author | L Kristin Newby | Q77796327 |
| | Stefan James | Q86735199 |
| | Renato Delascio Lopes | Q90906040 |
| | Jeffrey B Washam | Q91797048 |
| | Shahyar Gharacholou | Q96242602 |
| | John H. Alexander | Q110877755 |
| P2860 | cites work | Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: | Q22242896 |
| | The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI | Q22252998 |
| | Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction | Q28185249 |
| | Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban | Q28185502 |
| | Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 |
| | Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial | Q28193186 |
| | Warfarin, aspirin, or both after myocardial infarction | Q28193836 |
| | Antithrombotic therapy after myocardial infarction | Q28193837 |
| | Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial | Q28195423 |
| | Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation | Q28213755 |
| | Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | Q28218789 |
| | ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction | Q28240355 |
| | Bivalirudin during primary PCI in acute myocardial infarction | Q28281179 |
| | Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) | Q28284905 |
| | Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes | Q28306261 |
| | Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 |
| | Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry | Q33437306 |
| | Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial | Q33611581 |
| | Current concepts of the pathogenesis of the acute coronary syndromes | Q34310339 |
| | Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial | Q34331649 |
| | Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). | Q35583786 |
| | Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview | Q35828309 |
| | Role of heparin in coronary thrombolysis | Q35956655 |
| | Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis | Q36864506 |
| | Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial | Q36935879 |
| | 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines | Q37055778 |
| | Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score | Q37156100 |
| | Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial | Q38408470 |
| | Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative | Q38465848 |
| | Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials | Q40414100 |
| | Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction | Q41376510 |
| | Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial | Q42025980 |
| | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy | Q42604256 |
| | Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). | Q43492693 |
| | Early versus delayed, provisional eptifibatide in acute coronary syndromes | Q44267128 |
| | The effect of warfarin on mortality and reinfarction after myocardial infarction | Q44339433 |
| | Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden | Q44883395 |
| | A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. | Q44928926 |
| | Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. | Q45173221 |
| | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. | Q45962608 |
| | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. | Q45995789 |
| | Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction | Q46049965 |
| | Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. | Q46209759 |
| | Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q46522912 |
| | Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 |
| | Comparison of fondaparinux and enoxaparin in acute coronary syndromes | Q46990542 |
| | Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction | Q46990548 |
| | National hospital discharge survey: annual summary, 1998. | Q50667443 |
| | Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, | Q50705176 |
| | Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. | Q51093369 |
| | Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. | Q51826453 |
| | ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary | Q56986933 |
| | Acute Coronary Care in the Elderly, Part I | Q57483864 |
| | Management of acute myocardial infarction in patients presenting with ST-segment elevation | Q61651499 |
| | Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy | Q71024544 |
| | Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction | Q71310542 |
| | Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators | Q73854850 |
| | Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative | Q80232541 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acute coronary syndrome | Q266018 |
| P304 | page(s) | 516-528 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician | |
| P478 | volume | 29 | |